- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Niederländisch
- Erschienen in
-
GLP-1-receptoragonisten en renoprotectie in type 2-diabetes ; volume:22 ; number:3 ; day:27 ; month:8 ; year:2024 ; pages:21-26 ; date:9.2024
Nederlands Tijdschrift voor Diabetologie ; 22, Heft 3 (27.8.2024), 21-26, 9.2024
- Klassifikation
-
Medizin, Gesundheit
- Urheber
-
H.A. Muskiet, Marcel
M. Apperloo, Ellen
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s12467-024-1567-6
- URN
-
urn:nbn:de:101:1-2411130734094.187506150050
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:38 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- H.A. Muskiet, Marcel
- M. Apperloo, Ellen
- SpringerLink (Online service)
Ähnliche Objekte (12)
GLP-1 - Therapiepotential bei Diabetes mellitus
GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries
Prediction of response to GLP-1 receptor agonist therapy in Japanese patients with type 2 diabetes
Timing of GLP-1 Receptor Agonist Initiation for Treatment of Type 2 Diabetes in the UK
Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
Type 2 diabetes is associated with impaired jejunal enteroendocrine GLP-1 cell lineage in human obesity
Engineering of a GLP-1 analogue peptide/anti-PCSK9 antibody fusion for type 2 diabetes treatment
Designing and computational analyzing of chimeric long-lasting GLP-1 receptor agonists for type 2 diabetes
Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus
GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data
GLP-1 Receptor Agonists for Type 2 Diabetes and Their Role in Primary Care: An Australian Perspective
Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER
GLP-1 - Therapiepotential bei Diabetes mellitus
GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries
Prediction of response to GLP-1 receptor agonist therapy in Japanese patients with type 2 diabetes
Timing of GLP-1 Receptor Agonist Initiation for Treatment of Type 2 Diabetes in the UK
Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
Type 2 diabetes is associated with impaired jejunal enteroendocrine GLP-1 cell lineage in human obesity
Engineering of a GLP-1 analogue peptide/anti-PCSK9 antibody fusion for type 2 diabetes treatment
Designing and computational analyzing of chimeric long-lasting GLP-1 receptor agonists for type 2 diabetes
Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus
GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data
GLP-1 Receptor Agonists for Type 2 Diabetes and Their Role in Primary Care: An Australian Perspective
Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER
GLP-1 - Therapiepotential bei Diabetes mellitus
GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries
Prediction of response to GLP-1 receptor agonist therapy in Japanese patients with type 2 diabetes
Timing of GLP-1 Receptor Agonist Initiation for Treatment of Type 2 Diabetes in the UK
Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
Type 2 diabetes is associated with impaired jejunal enteroendocrine GLP-1 cell lineage in human obesity
Engineering of a GLP-1 analogue peptide/anti-PCSK9 antibody fusion for type 2 diabetes treatment
Designing and computational analyzing of chimeric long-lasting GLP-1 receptor agonists for type 2 diabetes
Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus
GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data
GLP-1 Receptor Agonists for Type 2 Diabetes and Their Role in Primary Care: An Australian Perspective